AI Article Synopsis
- The incidence of melanoma, a highly aggressive skin cancer, has significantly risen in recent decades, leading to delayed diagnoses that affect patient outcomes.
- Despite established diagnostic criteria, melanoma remains difficult to identify due to its heterogeneous nature across clinical, histopathological, and molecular levels.
- Recent studies are exploring various fields like genomics, proteomics, and metabolomics to identify potential biomarkers for improved diagnosis and monitoring of melanoma progression.
Article Abstract
The incidence of melanoma, a very aggressive skin cancer, has increased over the past few decades. Although there are well-established clinical, dermoscopic and histopathological criteria, the diagnosis is often performed late, which has important implications on the patient's clinical outcome. Unfortunately, melanoma is one of the most challenging tumors to diagnose because it is a heterogeneous neoplasm at the clinical, histopathological, and molecular level. The use of reliable biomarkers for the diagnosis and monitoring of disease progression is becoming a standard of care in modern medicine. In this review, we discuss the latest studies, which highlight findings from the genomics, epitranscriptomics, proteomics and metabolomics areas, pointing out different genes, molecules and cells as potential diagnostic and prognostic biomarkers in cutaneous melanoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505119 | PMC |
| http://dx.doi.org/10.3390/jpm12091506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!